$23.17
Today
as of Sep 4, 16:46 ET
Last 30 days
Recent Press Releases & News
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Can Bicara (BCAX) Commercialize Ficera? Breakthrough 3-Year Data Faces Execution Risk in C-Suite Overhaul
BMO Capital Initiates Bicara Therapeutics at Outperform
Overview
52-week range
$10
$31
62% of range
Avg surprise (last 3)
-36.0%
Avg reaction (last 2)
-3.3%
50% positive
Latest IV / EM
58%
EM ±9.1% · $23 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.82 | — | — | — | — | financials |
| Mon May 11, 2026 | Mar/2026 | $-0.93 | $-0.64 | -45.3% | -36.8% | +1.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.67 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.50 | $-0.54 | +7.4% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.68 | $-0.40 | -70.0% | — | -8.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.60 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-19.01 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-18.94 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-38.23 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-60M | $-60M | — | $-41M | $-32M | $-42M | — | $-21M |
| Net income | $-55M | $-56M | — | $-36M | $-27M | $-37M | — | $-17M |
| EPS (diluted) | $-0.82 | $-0.93 | — | $-0.67 | $-0.50 | $-0.68 | — | $-1.60 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $97M | $323M | $97M | $172M | $437M | $462M | $490M | $521M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $504M | $545M | $422M | $297M | $444M | $471M | $503M | $522M |
| Total assets | $512M | $554M | $431M | $425M | $454M | $478M | $510M | $524M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $43M | $40M | $30M | $22M | $18M | $19M | $18M | $15M |
| Total equity | $469M | $514M | $401M | $403M | $435M | $459M | $492M | $510M |